Format

Send to

Choose Destination
Rev Neurol. 2006 May 1-15;42(9):549-55.

[The neurochemistry and neuropharmacology of diffuse Lewy body disease].

[Article in Spanish]

Author information

1
Department of Medicine-Neurology, Hospital Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, E-28030 Madrid, Spain.

Abstract

INTRODUCTION AND DEVELOPMENT:

The main neurochemical alteration in diffuse Lewy body disease (DLBD) is the cholinergic deficit in the cerebral cortex, which involves mainly cholin-acetyl-transferase. There have been also described dopamine deficiency and alterations affecting other neurotransmitters and neuromodulators, such as serotonin, noradrenaline, neuropeptides, etc. Cerebral perfusion and glucose metabolism studies usually show diffuse hypoperfusion or hypometabolism, with higher alteration of associative cortex, including occipital involvement. Several studies have shown increased markers of oxidative stress in brain and other tissues, suggesting its possible role in the pathogenesis of DLBD.

CONCLUSIONS:

Acetylcholinesterase inhibitors seem to improve cognitive and conductual symptoms, although their usefulness according evidence-based medicine criteria is weak. Some patients need atypical neuroleptics at low doses to get the symptomatic control of conductual alterations.

PMID:
16676279
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Viguera Editores, S. L.
Loading ...
Support Center